{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:27:42Z","timestamp":1782764862240,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejpb.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T23:30:30Z","timestamp":1629847830000},"page":"38-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A novel 111indium-labeled dual carbonic anhydrase 9-targeted probe as a potential SPECT imaging radiotracer for detection of hypoxic colorectal cancer cells"],"prefix":"10.1016","volume":"168","author":[{"given":"Siao-Syun","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Zung","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hsia","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Feng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Tang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chieh","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing\u2011Hwa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2021.08.004_b0005","doi-asserted-by":"crossref","unstructured":"F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin. 68 (2018) 394-424.","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.ejpb.2021.08.004_b0010","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.ejpb.2021.08.004_b0015","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Can. J Clin."},{"key":"10.1016\/j.ejpb.2021.08.004_b0020","first-page":"599","article-title":"NCCN guidelines updates: management of metastatic colorectal cancer","volume":"17","author":"Messersmith","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.ejpb.2021.08.004_b0025","article-title":"Management of colorectal cancer","volume":"366","author":"Brown","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.ejpb.2021.08.004_b0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41419-019-1769-9","article-title":"Clinical update on head and neck cancer: molecular biology and ongoing challenges","volume":"10","author":"Alsahafi","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejpb.2021.08.004_b0035","first-page":"382","article-title":"The hypoxic tumor microenvironment: a driving force for breast cancer progression","volume":"2016","author":"Semenza","year":"1863","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.ejpb.2021.08.004_b0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djx160","article-title":"Targeting hypoxia to improve non-small cell lung cancer outcome","volume":"110","author":"Salem","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.ejpb.2021.08.004_b0045","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.2147\/IJN.S140462","article-title":"Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment","volume":"13","author":"Graham","year":"2018","journal-title":"Int J Nanomedicine."},{"key":"10.1016\/j.ejpb.2021.08.004_b0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.semnuclmed.2014.10.004","article-title":"Optimizing hypoxia detection and treatment strategies","volume":"45","author":"Koch","year":"2015","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.ejpb.2021.08.004_b0055","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1089\/ars.2013.5378","article-title":"The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities","volume":"21","author":"Walsh","year":"2014","journal-title":"Antioxid Redox Signal."},{"key":"10.1016\/j.ejpb.2021.08.004_b0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-3-319-38810-6_15","article-title":"Comparing the effectiveness of methods to measure oxygen in tissues for prognosis and treatment of cancer","volume":"923","author":"Flood","year":"2016","journal-title":"Adv Exp Med Biol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0065","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/0008-5472.CAN-15-2818","article-title":"Oxygen-enhanced MRI is a major advance in tumor hypoxia imaging","volume":"76","author":"Dewhirst","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2021.08.004_b0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.08.002","article-title":"Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use","volume":"31","author":"Pastorek","year":"2015","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.ki.5002020","article-title":"The role of carbonic anhydrases in renal physiology","volume":"71","author":"Purkerson","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejpb.2021.08.004_b0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signalling in cancer and approaches to enforce tumour regression","volume":"441","author":"Pouyssegur","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.ejpb.2021.08.004_b0085","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/molecules20022323","article-title":"Targeting carbonic anhydrase IX activity and expression","volume":"20","author":"Mahon","year":"2015","journal-title":"Molecules."},{"key":"10.1016\/j.ejpb.2021.08.004_b0090","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1172\/JCI126044","article-title":"Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies","volume":"129","author":"Dewhirst","year":"2019","journal-title":"J Clin Invest."},{"key":"10.1016\/j.ejpb.2021.08.004_b0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/molecules23051045","article-title":"Cancer drug development of carbonic anhydrase inhibitors beyond the active site","volume":"23","author":"Singh","year":"2018","journal-title":"Molecules."},{"key":"10.1016\/j.ejpb.2021.08.004_b0100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.ejpb.2021.08.004_b0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.addr.2017.05.006","article-title":"Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment","volume":"119","author":"David","year":"2017","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.ejpb.2021.08.004_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015962","article-title":"A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology","volume":"5","author":"Askoxylakis","year":"2010","journal-title":"PLoS One."},{"key":"10.1016\/j.ejpb.2021.08.004_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038279","article-title":"Optimization of a novel peptide ligand targeting human carbonic anhydrase IX","volume":"7","author":"Rana","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.ejpb.2021.08.004_b0120","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.7150\/thno.20982","article-title":"Cancer radiotheranostics targeting carbonic anhydrase-IX with (111)In- and (90)Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy","volume":"8","author":"Iikuni","year":"2018","journal-title":"Theranostics."},{"key":"10.1016\/j.ejpb.2021.08.004_b0125","article-title":"Synthesis and evaluation of indium-111-labeled imidazothiadiazole sulfonamide derivative for single photon emission computed tomography imaging targeting carbonic anhydrase-IX","volume":"30","author":"Iikuni","year":"2020","journal-title":"Bioorg Med Chem Lett."},{"key":"10.1016\/j.ejpb.2021.08.004_b0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.radonc.2013.06.018","article-title":"Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs","volume":"108","author":"Dubois","year":"2013","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0135","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bmcl.2018.01.060","article-title":"Acetazolamide-based [(18)F]-PET tracer: In vivo validation of carbonic anhydrase IX as a sole target for imaging of CA-IX expressing hypoxic solid tumors","volume":"28","author":"More","year":"2018","journal-title":"Bioorg Med Chem Lett."},{"key":"10.1016\/j.ejpb.2021.08.004_b0140","doi-asserted-by":"crossref","first-page":"8168","DOI":"10.3748\/wjg.v22.i36.8168","article-title":"Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas","volume":"22","author":"Viikila","year":"2016","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nchem.2158","article-title":"Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation","volume":"7","author":"Wichert","year":"2015","journal-title":"Nat Chem."},{"key":"10.1016\/j.ejpb.2021.08.004_b0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1580\/1080-6032-17.2.87","article-title":"Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial","volume":"17","author":"Hillenbrand","year":"2006","journal-title":"Wilderness Environ Med."},{"key":"10.1016\/j.ejpb.2021.08.004_b0155","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.ejpb.2021.08.004_b0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/03602532.2011.638303","article-title":"Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer","volume":"44","author":"Marin","year":"2012","journal-title":"Drug Metab Rev."},{"key":"10.1016\/j.ejpb.2021.08.004_b0165","doi-asserted-by":"crossref","first-page":"20130676","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br J Radiol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0170","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1021\/acs.chemrev.6b00525","article-title":"Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia","volume":"117","author":"Liu","year":"2017","journal-title":"Chem Rev."},{"key":"10.1016\/j.ejpb.2021.08.004_b0175","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1021\/jacs.5b04097","article-title":"Ultrasensitive near-infrared fluorescence-enhanced probe for in vivo nitroreductase imaging","volume":"137","author":"Li","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2021.08.004_b0180","doi-asserted-by":"crossref","first-page":"94969","DOI":"10.18632\/oncotarget.21662","article-title":"(18)F-Fluoromisonidazole in tumor hypoxia imaging","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ejpb.2021.08.004_b0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40336-017-0231-1","article-title":"Molecular mechanisms of hypoxia in cancer","volume":"5","author":"Challapalli","year":"2017","journal-title":"Clin Transl Imaging."},{"key":"10.1016\/j.ejpb.2021.08.004_b0190","first-page":"106","article-title":"Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside","volume":"46","author":"Piert","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2021.08.004_b0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/157340908783769265","article-title":"PET and SPECT imaging of tumor biology: new approaches towards oncology drug discovery and development","volume":"4","author":"Van Dort","year":"2008","journal-title":"Curr Comput Aided Drug Des."},{"key":"10.1016\/j.ejpb.2021.08.004_b0200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13550-019-0543-4","article-title":"Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [(18)F]HX4 PET imaging study in colorectal cancer xenografts","volume":"9","author":"De Bruycker","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejpb.2021.08.004_b0205","first-page":"58","article-title":"Focus on the controversial aspects of (64)Cu-ATSM in tumoral hypoxia mapping by PET imaging","volume":"2","author":"Colombie","year":"2015","journal-title":"Front. Med. (Lausanne)."},{"key":"10.1016\/j.ejpb.2021.08.004_b0210","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2967\/jnumed.115.155663","article-title":"64Cu-ATSM reflects pO2 levels in human head and neck cancer xenografts but not in colorectal cancer xenografts: comparison with 64CuCl2","volume":"57","author":"Li","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2021.08.004_b0215","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.nucmedbio.2009.02.006","article-title":"Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects","volume":"36","author":"Basken","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/2191-219X-3-42","article-title":"Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer","volume":"3","author":"O'Donoghue","year":"2013","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejpb.2021.08.004_b0225","doi-asserted-by":"crossref","first-page":"36139","DOI":"10.18632\/oncotarget.5684","article-title":"Sulfonamide derivative targeting carbonic anhydrase IX as a nuclear imaging probe for colorectal cancer detection in vivo","volume":"6","author":"Guan","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.ejpb.2021.08.004_b0230","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/14756366.2017.1308928","article-title":"Design, synthesis and evaluation of (18)F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging","volume":"32","author":"Zhang","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejpb.2021.08.004_b0235","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acs.molpharmaceut.5b00934","article-title":"PET imaging of carbonic anhydrase IX expression of HT-29 tumor xenograft mice with (68)Ga-labeled benzenesulfonamides","volume":"13","author":"Lau","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2021.08.004_b0240","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","article-title":"A modeling analysis of the effects of molecular size and binding affinity on tumor targeting","volume":"8","author":"Schmidt","year":"2009","journal-title":"Mol. Can. Ther."},{"key":"10.1016\/j.ejpb.2021.08.004_b0245","first-page":"466","article-title":"Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies","volume":"19","author":"Brouwers","year":"2004","journal-title":"Can. Biother Radiopharm."},{"key":"10.1016\/j.ejpb.2021.08.004_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010857","article-title":"Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts","volume":"5","author":"Carlin","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2021.08.004_b0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.apradiso.2018.10.021","article-title":"Radiolabeling of the antibody IgG M75 for epitope of human carbonic anhydrase IX by (61)Cu and (64)Cu and its biological testing","volume":"143","author":"Cepa","year":"2019","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.ejpb.2021.08.004_b0260","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.7150\/thno.21848","article-title":"Past, present, and future: development of theranostic agents targeting carbonic anhydrase IX","volume":"7","author":"Lau","year":"2017","journal-title":"Theranostics."},{"key":"10.1016\/j.ejpb.2021.08.004_b0265","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1021\/acs.molpharmaceut.8b01120","article-title":"Development of the (99m)Tc-hydroxamamide complex as a probe targeting carbonic anhydrase IX","volume":"16","author":"Iikuni","year":"2019","journal-title":"Mol Pharm."},{"key":"10.1016\/j.ejpb.2021.08.004_b0270","article-title":"Synthesis and evaluation of novel technetium-99m-hydroxamamide complex based on imidazothiadiazole sulfonamide targeting carbonic anhydrase-IX for tumor imaging","volume":"30","author":"Iikuni","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejpb.2021.08.004_b0275","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nucmedbio.2020.11.008","article-title":"Synthesis and evaluation of (68)Ga-labeled imidazothiadiazole sulfonamide derivatives for PET imaging of carbonic anhydrase-IX","volume":"93","author":"Nakashima","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0280","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708699","article-title":"Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis","volume":"10","author":"Greenhough","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejpb.2021.08.004_b0285","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bju.12950","article-title":"Renal cell cancer histological subtype distribution differs by race and sex","volume":"117","author":"Lipworth","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.ejpb.2021.08.004_b0290","doi-asserted-by":"crossref","unstructured":"M. Pichler, G.C. Hutterer, T.F. Chromecki, J. Jesche, K. Kampel-Kettner, K. Eberhard, et al., Trends of stage, grade, histology and tumour necrosis in renal cell carcinoma in a European centre surgical series from 1984 to 2010, J Clin Pathol. 65 (2012) 721-724.","DOI":"10.1136\/jclinpath-2012-200797"},{"key":"10.1016\/j.ejpb.2021.08.004_b0295","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","article-title":"Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity","volume":"67","author":"Shuch","year":"2015","journal-title":"Eur Urol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","article-title":"Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy","volume":"58","author":"Stillebroer","year":"2010","journal-title":"Eur Urol."},{"key":"10.1016\/j.ejpb.2021.08.004_b0305","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2967\/jnumed.115.170514","article-title":"A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo","volume":"57","author":"Krall","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2021.08.004_b0310","doi-asserted-by":"crossref","first-page":"56471","DOI":"10.18632\/oncotarget.10602","article-title":"[64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma","volume":"7","author":"Minn","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.ejpb.2021.08.004_b0315","doi-asserted-by":"crossref","first-page":"33733","DOI":"10.18632\/oncotarget.5254","article-title":"Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.ejpb.2021.08.004_b0320","first-page":"89","article-title":"The expression of G250\/mn\/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells","volume":"7","author":"Li","year":"2001","journal-title":"Clin Cancer Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:43:23Z","timestamp":1760546603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121002083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":64,"alternative-id":["S0939641121002083"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.08.004","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel 111indium-labeled dual carbonic anhydrase 9-targeted probe as a potential SPECT imaging radiotracer for detection of hypoxic colorectal cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}